These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 9161784

  • 1. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ, Gandara DR, Hesketh AM, Edelman M, Webber LM, McManus M, Hainsworth JD.
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [Abstract] [Full Text] [Related]

  • 2. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
    Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR.
    Support Care Cancer; 2000 Jan; 8(1):46-8. PubMed ID: 10650897
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H, Hesketh P, Cohn J, Moriconi W, Ryan T, Friedman C, Fitts D.
    Cancer J Sci Am; 1996 Jan; 2(2):85-90. PubMed ID: 9166505
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ.
    N Engl J Med; 1999 Jan 21; 340(3):190-5. PubMed ID: 9917226
    [Abstract] [Full Text] [Related]

  • 6. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
    Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R.
    Bone Marrow Transplant; 1999 Feb 21; 23(3):265-9. PubMed ID: 10084258
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.
    Cancer; 2002 Jun 01; 94(11):3032-41. PubMed ID: 12115394
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct 01; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

  • 10. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C.
    Cancer J Sci Am; 1998 Oct 01; 4(1):52-8. PubMed ID: 9467047
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS, Eisenberg PD, Fitts D, Friedman C, Wilson-Lynch K, Yocom K.
    Cancer; 1996 Jul 01; 78(1):144-51. PubMed ID: 8646710
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW, Dijkstra HJ, Blijham GH, van der Wall E, Fehmers MC, Keizer HJ, Nortier JW, Siegenbeek van Heukelom L, Slee PH, Veenhof CH.
    Neth J Med; 1992 Jun 01; 40(5-6):221-6. PubMed ID: 1331830
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of tropisetron and dexamethasone in the prevention of cisplatin-induced emesis.
    Voravud N, Suwanrusmee H.
    J Med Assoc Thai; 2000 Jun 01; 83(6):668-75. PubMed ID: 10932495
    [Abstract] [Full Text] [Related]

  • 15. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U, Drechsler S, Eggert J, Gosse H, Ukena D, Imhoff W, Faerber L.
    Semin Oncol; 1994 Oct 01; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [Abstract] [Full Text] [Related]

  • 16. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P.
    J Med Assoc Thai; 2006 Oct 01; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
    Ho CL, Su WC, Hsieh RK, Lin ZZ, Chao TY.
    Jpn J Clin Oncol; 2010 Apr 01; 40(4):294-301. PubMed ID: 20026457
    [Abstract] [Full Text] [Related]

  • 18. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb 01; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 19. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group.
    Cancer; 2003 Jun 15; 97(12):3090-8. PubMed ID: 12784346
    [Abstract] [Full Text] [Related]

  • 20. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    J Clin Oncol; 2003 Nov 15; 21(22):4105-11. PubMed ID: 14559891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.